Dateline: Tue, 12 Jun 2007
freeNewsArticles Story Summary: “KENILWORTH, N.J. – June 12 (SEND2PRESS NEWSWIRE) — 3C Company, Inc., a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution.”
A R T I C L E:
Pharmaceutical Industry Embraces Business Intelligence Tools to Manage Challenges of Culture, Regulation, and Patient Population Variances in their Global Development Programs
KENILWORTH, N.J. – June 12 (SEND2PRESS NEWSWIRE) — 3C Company, Inc. (www.3cpharma.com), a leading provider of Business Performance Optimization (BPO) solutions to the Life Sciences Industry, announces today the release of a new module to its highly successful Clintelligence(R) Business Intelligence Solution.
“There is no question that we must expand our research programs into new areas of the world, to ensure that patients in less exposed parts of the world have the benefits of being part of the drug development process,” states the Executive Director of Global Clinical Research Operations at a Top 5 ranked Global Pharmaceutical. “This means taking on the challenges of placing these trials in areas that have different regulatory environments, different procedures and sometimes very different patient treatment regimens. These all add complexity to the management of a schedule and add risk to our goal of achieving FDA approval of our products in a timely and efficient manner.”
“Where a drug is invented and where it is manufactured is much less critical than where research patients are located,” explains Karen Briegs, a Sr. Director at 3C.
“Conducting research in regions that have different rules of the game requires careful planning and close monitoring to avoid costly delays. We’ve addressed this complexity by creating an entire module within Clintelligence that focuses on the activities that occur on a global basis, and that highlights at a country-by-country level any risks in real-time. This is a significant addition to the product for any organization engaged in global research.”
About Clintelligence
Clintelligence(R) is the only commercially available Pharmaceutical Business Intelligence product that covers all of the critical topics across Research and Development (R&D).
Clintelligence uses maps, graphs, reports and analytical modules in an interactive, customizable web-portal format for easily understandable and actionable information. Clintelligence leverages industry standard technology components and can be implemented rapidly in any sized company.
For more information on Clintelligence(R) go to www.clintelligence.com.
###
Copyright © 2007 by 3C Company, Inc. and Send2Press® Newswire, a service of Neotrope® – all rights reserved. Information believed accurate but not guaranteed. Sourced on: freeNewsArticles.com.
• Story Title: U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas – New Clintelligence(R) Alignment Module Advances Global Management
• REFERENCE KEYWORDS/TERMS: Pharmaceutical Business Intelligence, , , 3C Company Inc, Drugs and Pharmaceuticals, , , .
IMPORTANT NOTICE: some content which is considered “old” or “archival” may reference an event which has already occurred; some content possibly considered “advertorial” may also reference a promotion or time-limited/sensitive offering, and in all of these instances certain material may no longer be valid. For notably stale content, you should directly contact the company/person mentioned in the text (3C Company, Inc.); this site cannot assist you with information about products/services mentioned in the news article, nor handle any complaints or other issues related to any person/company mentioned or promoted in the above text. Information believed accurate but not guaranteed as of original date of story [Tue, 12 Jun 2007 18:00:00 GMT].
USE THIS CONTENT FOR FREE: To use this content in your newspaper, broadcast outlet, news portal, blog/ezine or similar, free of cost, CLICK HERE to learn how.